Area
Nervous SystemIndication
Alzheimer diseaseSystem
In vitroCaenorhabditis elegans-AD and other neurogenerative diseases strains
Applications
Available strains:
- CL2006. dvIs2 [pCL12(unc-54/human Abeta peptide 1-42 minigene) + pRF4].
- CL2122. dvIs15 [(pPD30.38) unc-54(vector) + (pCL26) mtl-2::GFP].
- CL2355. dvIs50 [pCL45 (snb-1::Abeta 1-42::3′ UTR(long) + mtl-2::GFP].
- BR6563. byIs161 [rab-3p::F3(delta)K280 + myo-2p::mCherry]. bkIs10 [aex-3p::h4R1NtauV337M + myo-2p::GFP].
– Study of molecular and biochemical characteristics of the disease. - AD drug evaluation from phenotype and molecular point of view.
- Drug validation for AD and other dementias.
Principal investigators
Mercè Pallàs, Christian Griñán-Ferré.Model relevance
Our competitive advantage is work with both relevant models in the neuroscience field, the C elegans as an in vitro model to evaluate toxicity and drug response and characteristic phenotypes for each neurodegenerative disease.
